THERAPEUTIC CLASS

Age and frailty in COVID-19 vaccine development

---

Older adults, particularly those who are frail or living in long-term care facilities, have been disproportionately affected by the COVID-19 pandemic.1 Vaccines that are safe and effective in this population have been eagerly anticipated. In The Lancet, Maheshi Ramasamy
and colleagues present results of the safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine in older adults (those older than 55 years).

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

LITERATURE

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Allergy & Immune System

Specific Detail Info

https://doi.org/10.1016/S0140-6736(20)32481-8

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment